Gilead Sciences: Great Quarter, Strong Anti-Viral Franchise Make It a Buy

Ryan Savitz submits:

Gilead Sciences (GILD) pleased its investors yet again with another quarter of great earnings. The biotechnology company from Foster City, California has truly proven to investors that they can withstand the tough economic conditions across the globe, even offering high priced drugs. More importantly, the company has built up a respectable reputation on the Street as being a “staple” biotech holding for anyone’s personal portfolio. As you have seen in my recent article concerning GDP Healthcare numbers that were reported, prescription-drug spending slowed to its lowest rate in 45 years. We will expand on how Gilead avoided industry-wide troubles later. For those anxious Gilead shareholders who were waiting on a Pfizer (PFE) buyout after

some talk that they would try to make a large acquisition in order to gain exposure to biotech, I am very sorry. But, no need to dump your shares, Gilead is here to stay.

A Glimpse from Above

Complete Story »
Go to Source

More Information: